Top Health Care Stocks <\/p>\n
JNJ -0.14% <\/p>\n
PZE +0.57% <\/p>\n
MRK +0.35% <\/p>\n
ABT +0.50% <\/p>\n
AMGN -0.26% <\/p>\n
Health care stocks were slightly higher with the NYSE Health Care Sector Index climbing about 0.1% and shares of health care companies in the S&P 500 advancing about 0.2% as a group. <\/p>\n
In company news, Heat Biologics ( HTBX ) rallied Monday after the biotech company today presented positive immunological data on its HS-410 drug candidate in certain forms of bladder cancer. <\/p>\n
According to the company, one of the patients participating in the Phase I trial showed a 70-fold rise in CD8+ \"killer\" T cell after six weeks of HS-140 treatment following surgery and growing to 750-fold increase after 21 weeks of treatment. <\/p>\n
The patient remains disease-free, HTBX said. A second patient experienced a non-specific immune infiltrate after seven weeks although a repeat biopsy at 13 weeks showed no further increase in the immune infiltrate. <\/p>\n
<\/p>\n
Continued here: <\/p>\n
Health Care Sector Update for 01\/26\/2015: HTBX,ATNM,MSTX<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Top Health Care Stocks JNJ -0.14% PZE +0.57% MRK +0.35% ABT +0.50% AMGN -0.26% Health care stocks were slightly higher with the NYSE Health Care Sector Index climbing about 0.1% and shares of health care companies in the S&P 500 advancing about 0.2% as a group. In company news, Heat Biologics ( HTBX ) rallied Monday after the biotech company today presented positive immunological data on its HS-410 drug candidate in certain forms of bladder cancer. According to the company, one of the patients participating in the Phase I trial showed a 70-fold rise in CD8+ \"killer\" T cell after six weeks of HS-140 treatment following surgery and growing to 750-fold increase after 21 weeks of treatment Continue reading